On June 6, the American Medical Association held a media briefing on anemia, funded by an unrestricted educational grant from Amgen, Inc. Topics included anemia and heart failure and new strategies for treating anemia associated with cancer treatment.
While most pharmacies gave test patients printed information about their drugs, the quality of the leaflets was uneven, according to a University of Wisconsin School of Pharmacy study.
ASHP drug error presentations' highlights
On June 7, the FDA announced that it had approved a supplemental New Drug Application for alosetron. The drug is approved for the treatment of women with severe diarrhea-predominant irritable bowel syndrome, who have failed to respond to conventional IBS therapy. Alosetron will become available again, possibly within the next 6 months, through a restricted marketing program.
Challenges of complying with HIPAA
FDA holds hearing to solicit ideas on risk management for drugs
Hospitals must use indicators in clinical/services and human resources to assess their staffing effectiveness under JCAHO standards
AstraZeneca comes under fire by Grey Panthers
Pfizer recently announced that it has received marketing approval from the US Food and Drug Administration for voriconazole (Vfend tablets) and voriconazole for injection (Vfend I.V.) for use in the treatment of invasive aspergillosis and the treatment of serious fungal infections caused by Scedosporium apiospermum and Fusarium spp in patients intolerant of, or refractory to, other therapy.
Avonex covered under Medicare's self-injectable policy
The US Food and Drug Administration (FDA) recently approved urofollitropin for injection, purified (Bravelle, Ferring Pharmaceuticals) for the treatment of infertility. Urofollitropin is a highly purified follicle-stimulating hormone derived from the urine of postmenopausal women
Pharmacists are facing a myriad of prescription discount cards in a high-stakes game
nacds launches pharmacy care index to aid patient compliance
nacds promotes pharmacy to his students
Medicare bill considers paying for oral cancer drugs
Georgia bill regulates PBMs
APA releases new guidelines to treat bipolar disorder.
Handheld devices let physicians compare drug prices when they are prescribing
NIOSH to publish safety alert related to cytotoxic drugs
Feds post quality of nursing homes on Web for consumers to comparison shop
Pharmacists feel they're gaining authority in some areas and lagging in others
PDUFA law renewal draws consumer protest
American Pain Society recommends using OxyContin to treat patients with arthritis.
Executives from Merck-Medco and Rite Aid speak at AMCP meeting on how to build constructive relationship with each other
drug topics selects costco as pharmacy chain of the year 2002
New Mexico law will allow psychologists to prescribe
New guidelines treat breast cancer.
NACDS proposes a one-card program but pharmacists have mixed reactions
pharmacy benefits trends in US
On March 8, 2002, the FDA announced the approval of interferon beta-1a (Rebif, Serono) for the treatment of relapsing forms of MS. The FDA based its approval on the results of two trials.